# Molnupiravir
**Molnupiravir** (development codes EIDD-2801, MK-4482; brand name Lagevrio) is an orally available, broad-spectrum antiviral drug that acts against [SARS-CoV-2](https://www.edgepedia.org/sars-cov-2) and other RNA viruses by inducing mutations in the viral genome during replication, a mechanism known as lethal mutagenesis.[1](https://www.nature.com/articles/s41594-021-00651-0) • [2](https://www.nature.com/articles/s41586-023-06649-6) It is an isopropyl ester prodrug (inactive compound converted into the active drug inside the body) of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC, EIDD-1931), which was originally identified in a screening campaign for antiviral molecules against influenza A virus and respiratory syncytial virus.[1](https://www.nature.com/articles/s41594-021-00651-0) • [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/)
| Key fact | Detail |
|---|---|
| Drug class | Nucleoside analog prodrug of β-d-N4-hydroxycytidine (NHC), targeting the viral RNA-dependent RNA polymerase (RdRp)[1](https://www.nature.com/articles/s41594-021-00651-0) |
| Mechanism | Two-step lethal mutagenesis: NHC triphosphate is incorporated instead of CTP or UTP, then directs incorporation of G or A from the template, producing mutated viral RNA[1](https://www.nature.com/articles/s41594-021-00651-0) |
| Mutation pattern | G-to-A and C-to-U transitions in viral RNA, documented for influenza virus and SARS-CoV-2[1](https://www.nature.com/articles/s41594-021-00651-0) |
| Spectrum | In vitro activity against murine hepatitis virus, respiratory syncytial virus, influenza A and B, MERS-CoV, SARS-CoV-2, VEEV, and Ebola (Filoviridae)[4](https://www.nature.com/articles/s41392-021-00837-4) • [5](https://www.nature.com/articles/s41573-023-00692-8) |
| Key trial result | MOVe-OUT phase 3: absolute risk reduction of 2.9% in hospitalization or death among unvaccinated outpatients; PANORAMIC found no reduction in hospitalization or death among vaccinated outpatients[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/) |
| Regulatory status | US emergency use authorization for Lagevrio issued 23 December 2021; Merck withdrew its European marketing authorization application on 21 June 2023[6](https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products) • [7](https://www.ema.europa.eu/en/medicines/human/EPAR/lagevrio) |
| Guideline position | WHO conditional recommendation for non-severe COVID-19 at high risk of hospitalization, with nirmatrelvir/ritonavir and remdesivir considered superior choices[8](https://www.bmj.com/content/370/bmj.m3379) |
## Mechanism of action
Molnupiravir differs from chain-terminating nucleoside antivirals in that it does not stop RNA synthesis; it corrupts it. Coronaviruses carry an exonucleolytic proofreading activity that removes misincorporated nucleotides from the nascent RNA 3′ end, which makes chain terminators generally ineffective against SARS-CoV-2.[1](https://www.nature.com/articles/s41594-021-00651-0) Biochemical and structural work by Florian Kabinger, Carina Stiller, and colleagues in [Patrick Cramer](https://www.edgepedia.org/patrick-cramer)'s laboratory at the Max Planck Institute for Biophysical Chemistry established a two-step model for how molnupiravir evades this proofreading.[1](https://www.nature.com/articles/s41594-021-00651-0)
In the first step, the viral RdRp uses the active form of the drug, NHC triphosphate (MTP), as a substrate instead of [cytidine triphosphate](https://www.edgepedia.org/cytidine-triphosphate) or uridine triphosphate. When G or A occupies the templating position, NHC monophosphate is incorporated into the growing RNA instead of C or U, and incorporation does not stall the polymerase, which continues to the end of the template.[1](https://www.nature.com/articles/s41594-021-00651-0) In the second step, the M-containing RNA serves as a template for synthesis of positive-strand genomic RNA, and the templating NHC directs incorporation of either G or A, but not C or U, into the new strand.[1](https://www.nature.com/articles/s41594-021-00651-0)
The structural basis is tautomeric (shifting between two chemical forms, enabling mispairing) ambiguity: NHC adopts different tautomeric forms, with the amino form pairing with G and the imino form pairing with A. Cryo-EM structures of RdRp–RNA complexes containing M-A and M-G base pairs in the active center, resolved at 3.3 Å and 3.2 Å overall with the active center at about 2.9 Å, provided the first direct visualization of NHC inside a polymerase and showed that both base pairs are stable and accommodated without major distortion of the complex.[1](https://www.nature.com/articles/s41594-021-00651-0) Because M incorporation and M-directed misincorporation are apparently not recognized by the viral exonuclease, the drug escapes proofreading, and the resulting mutated positive-strand RNAs are predicted not to support formation of functional viruses, the error catastrophe model of antiviral action.[1](https://www.nature.com/articles/s41594-021-00651-0)
This mechanism is conceptually similar to that proposed for favipiravir but entirely distinct from remdesivir, which impairs RdRp progression after a delay rather than inducing mutations.[1](https://www.nature.com/articles/s41594-021-00651-0) Because the target is the conserved viral polymerase and the drug does not select for resistant variants in the way inhibitors of a single binding site do, molnupiravir has a high barrier to the development of viral resistance.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/)
## Development
Molnupiravir was originally designed for the treatment of alphavirus infections and was repurposed for COVID-19 as the pandemic spread, with the development timeline moved forward significantly. A licensing deal was concluded with Ridgeback Therapeutics, a biotechnology company that had recently completed development of an Ebola therapeutic in March 2020.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC8277160/) NHC itself has a broad antiviral spectrum in vitro that includes SARS-CoV-2 and other human coronaviruses, and the EIDD-2801 prodrug was synthesized to increase oral bioavailability.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/) Preclinical work showed inhibition of SARS-CoV-2 replication in human lung tissue, blocked transmission in ferrets, and reduced viral RNA in patients.[1](https://www.nature.com/articles/s41594-021-00651-0)
## Clinical evidence
Results published in December 2021 showed a significant reduction in hospitalization or death among unvaccinated outpatients, with an absolute risk reduction of 2.9%; this fell short of the 6.8% absolute risk reduction suggested by an earlier interim analysis.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/)
The two trials differed in population and dominant variants, with MOVe-OUT recruiting mainly unvaccinated patients during delta, gamma, and mu circulation and PANORAMIC recruiting vaccinated patients during the omicron wave, differences that contributed to the lower event rates in PANORAMIC.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/) A Cochrane review covering 11 randomized trials with 31,272 participants, mostly outpatients with mild to moderate COVID-19, assessed these effects up to April 2024.[12](https://www.cochrane.org/evidence/CD015381_molnupiravir-antiviral-medicine-safe-and-effective-treating-people-covid-19)
## Regulatory status and guideline recommendations
The FDA issued an emergency use authorization for Lagevrio (molnupiravir) on 23 December 2021 for the treatment of mild-to-moderate COVID-19 in certain adults at high risk of progression to severe disease for whom alternative treatment options are not accessible or clinically appropriate.[6](https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products) In Europe, the CHMP concluded that the clinical benefit of Lagevrio in adults with COVID-19 not receiving supplemental oxygen at increased risk of severe disease had not been demonstrated, and Merck Sharp & Dohme B.V. withdrew its marketing authorization application on 21 June 2023.[7](https://www.ema.europa.eu/en/medicines/human/EPAR/lagevrio)
The WHO living guideline issued a conditional (weak) recommendation in favor of molnupiravir for patients with non-severe COVID-19 at high risk of hospitalization, while judging that nirmatrelvir/ritonavir and remdesivir represent superior choices because of greater reductions in hospitalization and safety concerns with molnupiravir.[8](https://www.bmj.com/content/370/bmj.m3379) The NIH COVID-19 Treatment Guidelines Panel similarly recommends molnupiravir as an alternative therapy only when ritonavir-boosted nirmatrelvir and remdesivir are not available, feasible, or clinically appropriate, because molnupiravir appears to have lower clinical efficacy.[13](https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf)
## Mutational signature and safety considerations
Because the drug works by mutagenesis, its footprint is visible in sequence data. A 2023 analysis in *Nature* reported that SARS-CoV-2 sequencing databases contain extensive evidence of molnupiravir mutagenesis, detectable as a characteristic mutational signature in global genomes, and noted that considerations of mechanism of action are important in the design and assessment of antiviral drugs.[2](https://www.nature.com/articles/s41586-023-06649-6)
Safety questions follow from the mechanism. Mutagenic ribonucleoside analogs might detrimentally affect cellular DNA synthesis in mammalian cells, and the mitochondrial DNA-dependent RNA polymerase can incorporate NHC monophosphate into RNA in vitro.[14](https://www.nature.com/articles/s41573-023-00672-y.pdf) • [1](https://www.nature.com/articles/s41594-021-00651-0) Fetal toxicity has been reported in animal studies, and the WHO guideline cites in vitro and animal evidence suggesting possible carcinogenesis, with no human data on long-term harms available.[13](https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf) • [8](https://www.bmj.com/content/370/bmj.m3379) On the virologic front, among participants who had culturable infectious virus present at the start of the study, cultures from those receiving molnupiravir were negative by day 3, suggesting a reduced likelihood of spreading virus carrying error-induced mutations.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/)
## References
1. [Kabinger, F., Stiller, C., Schmitzová, J., et al. (2021). Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology 28, 740–746.](https://www.nature.com/articles/s41594-021-00651-0)
2. [A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature (2023).](https://www.nature.com/articles/s41586-023-06649-6)
3. [Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320168/)
4. [A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe. Signal Transduction and Targeted Therapy (2021).](https://www.nature.com/articles/s41392-021-00837-4)
5. [Accelerating antiviral drug discovery: lessons from COVID-19. Nature Reviews Drug Discovery (2023).](https://www.nature.com/articles/s41573-023-00692-8)
6. [Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products, FDA.](https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products)
7. [Lagevrio, European Medicines Agency.](https://www.ema.europa.eu/en/medicines/human/EPAR/lagevrio)
8. [A living WHO guideline on drugs for covid-19 (2020–2023). The BMJ.](https://www.bmj.com/content/370/bmj.m3379)
9. [Molnupiravir: Mechanism of action, clinical, and translational science. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/)
10. [Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8277160/)
11. [Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC). The Lancet / PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC9779781/)
12. [Is molnupiravir safe and effective in treating people with COVID-19? Cochrane.](https://www.cochrane.org/evidence/CD015381_molnupiravir-antiviral-medicine-safe-and-effective-treating-people-covid-19)
13. [Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, NIH.](https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf)
14. [Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery (2023).](https://www.nature.com/articles/s41573-023-00672-y.pdf)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Anti-infective drugs and resistance › Antiviral, antifungal, and antiparasitic drugs*
*Initially written Sep 17, 2026 · Reviewed: Sep 17, 2026; Oct 21, 2026 · Edited: Sep 17, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license